UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Epilepsy Behav. 2012 Mar;23(3):370-2. doi: 10.1016/j.yebeh.2011.11.030. Epub 2012 Feb 17.
This is a non-randomized open assessment of eicosapentaenoic acid (EPA) supplementation in ten people (five males) with refractory focal seizures. Each received 1000 mg of EPA daily for 3 months. Six people had fewer seizures during the supplementation period compared with baseline (range 12 to 59% reduction) and one other person had markedly reduced seizure severity. The mean reduction in seizure frequency was 16% (95% CI - 10% to 35%, p=0.26). With the small number of participants and open nature of the study, interpretation of the results is difficult, but a possible weak effect of EPA on seizures cannot be discounted. Further examination of EPA supplementation should be undertaken with larger numbers of people in controlled trials. Higher doses and longer duration of treatment should be considered.
这是一项针对十名（五男）难治性局灶性癫痫患者的二十碳五烯酸（EPA）补充的非随机开放评估。每个人每天接受 1000 毫克 EPA，持续 3 个月。与基线相比，六名患者在补充期间癫痫发作次数减少（范围 12%至 59%减少），另一名患者癫痫发作严重程度明显降低。癫痫发作频率的平均减少率为 16%（95%CI-10%至 35%，p=0.26）。由于参与者人数少且研究为开放性，因此难以解释结果，但不能排除 EPA 对癫痫发作可能有微弱的作用。应在对照试验中使用更多的人进一步检查 EPA 补充剂。应考虑更高的剂量和更长的治疗持续时间。
